151 related articles for article (PubMed ID: 21062978)
1. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract][Full Text] [Related]
2. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
4. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
6. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
[TBL] [Abstract][Full Text] [Related]
7. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
[TBL] [Abstract][Full Text] [Related]
8. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.
Malhotra S; Lapointe J; Salari K; Higgins JP; Ferrari M; Montgomery K; van de Rijn M; Brooks JD; Pollack JR
PLoS One; 2011; 6(5):e20293. PubMed ID: 21629784
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression.
Schaefer-Klein JL; Murphy SJ; Johnson SH; Vasmatzis G; Kovtun IV
PLoS One; 2015; 10(11):e0142327. PubMed ID: 26560244
[TBL] [Abstract][Full Text] [Related]
10. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.
Goltz D; Montani M; Braun M; Perner S; Wernert N; Jung K; Dietel M; Stephan C; Kristiansen G
Pathology; 2015 Dec; 47(7):629-36. PubMed ID: 26517642
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
13. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
14. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
[TBL] [Abstract][Full Text] [Related]
16. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
[TBL] [Abstract][Full Text] [Related]
19. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
20. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]